Heron Therapeutics is riding a push to treat pain without opioids, and new billing and policy changes could make it easier for hospitals to use its key medicines. But big borrowing costs, dependence on only a few products, and potential share dilution could limit how much of that upside reaches shareholders.Read more
Heron Therapeutics is trying to grow demand for its pain and nausea medicines as hospitals look for options that reduce opioid use, but the business still leans heavily on just a few products. A closer look at reimbursement rules, pricing pressure, and rising copycat competition shows why profits could be harder to sustain than the recent progress suggests.Read more
Heron Therapeutics could see a faster rollout of its non-opioid pain and supportive care medicines as insurers and regulators make it easier for hospitals and clinics to get paid for using them. The upside comes with real bumps in the road, though, including leaning heavily on a small set of products, pricing pushback, and questions about what comes next in the pipeline.Read more
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.
